Equities Analysts Offer Predictions for Immunic Q3 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for Immunic in a report released on Thursday, August 13th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.74) for the quarter, up from their previous estimate of ($2.21). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Immunic’s Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($3.18) EPS, FY2027 earnings at ($2.47) EPS, FY2028 earnings at ($1.45) EPS, FY2029 earnings at ($0.53) EPS and FY2030 earnings at $0.40 EPS.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36.

A number of other brokerages have also recently commented on IMUX. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a report on Monday, May 4th. Wedbush initiated coverage on shares of Immunic in a research note on Monday. They set an “outperform” rating and a $45.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. B. Riley Financial reduced their price objective on Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Finally, Roth Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Immunic in a report on Thursday, May 14th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immunic has a consensus rating of “Buy” and an average price target of $47.25.

Immunic Trading Down 0.2%

IMUX opened at $16.03 on Monday. The company has a market cap of $218.65 million, a price-to-earnings ratio of -3.66 and a beta of 1.41. The company’s 50 day moving average is $14.53 and its 200 day moving average is $12.16. Immunic has a 12-month low of $5.06 and a 12-month high of $16.86.

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. OMERS ADMINISTRATION Corp purchased a new position in Immunic during the first quarter valued at approximately $187,000. Avidity Partners Management LP increased its stake in shares of Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after purchasing an additional 2,000,000 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Immunic in the first quarter worth $1,020,000. CTC Alternative Strategies Ltd. bought a new stake in shares of Immunic during the 1st quarter valued at $27,000. Finally, Connective Capital Management LLC bought a new stake in shares of Immunic during the 4th quarter valued at $161,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.